PDCD1 and cancer: Despite the well-known benefits of PD-1 and PD-L1 inhibitors, early diagnosis of irAEs remains a critical challenge in oncology practice because clinical presentations of irAEs may appear similar to cancer progression or exacerbation of underlying comorbid conditions often present in patients with advanced cancer [7,10].